Core Insights - The divestiture of Coflex and Paradigm Spine assets to Companion Spine for $21.4 million signifies a strategic shift towards focusing exclusively on high-margin core biologics [1] - Management has successfully achieved a multi-year goal of self-sustainability, reporting positive net income, adjusted EBITDA, and cash flow through disciplined operational execution [1] - Q4 performance was affected by the early closing of the Companion Spine deal, resulting in a loss of approximately $2 million in anticipated revenue for the period [1] Strategic Focus - The company is transitioning from a phase of internal consolidation and manufacturing optimization to one of aggressive top-line growth pursuit [1] - Strategic differentiation is now centered on being a comprehensive partner in regenerative medicine, providing solutions across all five major orthobiologic categories [1] Commercial Expansion - The company is expanding its commercial reach by doubling the regional sales force and increasing investments in the national accounts team to drive institutional adoption [1]